← TAKEDA PHARMACEUTICAL CO LTD (TKPHF) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
Pharmaceutical Preparations · market cap $59.2B · as of 2026-07-09
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-31 (est.)
Phase 3
Pipeline
20
programs
Upcoming events
8
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
Takeda Pharmaceutical (TKPHF) is a large-cap global biopharmaceutical company with ~47,455 employees and a market cap of approximately $47.7B. The company operates a broad, late-stage pipeline spanning oncology, immunology, gastroenterology, neuroscience, and rare diseases, with several high-importance catalysts clustered in the 2026–2027 window. Key near-term binary events include Phase 3 readouts for TAK-861 (narcolepsy) and TAK-788 in Q4 2026, and a Phase 3 Maribavir readout in early 2027.
The catalyst path
- 2026-10-31 (est.)Phase 3 · TAK-788imp 9/10
- 2026-11-30 (est.)Phase 2 · TAK-360imp 7/10
- 2026-11-30 (est.)Phase 3 · TAK-360imp 9/10
- 2026-12-15 (est.)Phase 2 · Ixazomibimp 7/10
- 2027-01-15 (est.)Phase 2 · FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)imp 7/10
- 2027-01-18 (est.)Phase 3 · Maribavirimp 9/10
- 2027-02-17 (est.)Phase 2 · TAK-279imp 7/10
- 2027-03-15 (est.)Phase 3 · FEIBAimp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| SHP655 | Phase 2 | Acquired Thrombotic Thrombocytopenic Purpura (aTTP) |
| NoV GI.1/GII.4 Bivalent VLP Vaccine | Phase 2 | Healthy Volunteers |
| B-MAD chemotherapy | Phase 2 | Extranodal NK/T-cell Lymphoma |
| TAK-935 | Phase 2 | Epilepsy |
| Ponatinib | Phase 3 | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) |
| FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) | Phase 2 | Colon Cancer |
| Colchicine, 0.6 mg PO BID | Phase 2 | Atrial Fibrillation |
| Relugolix | Phase 3 | Uterine Fibroids |
| Apremilast | Phase 3 | Plaque Psoriasis |
| Glimepiride and Metformin | Phase 3 | Diabetes Mellitus |
| Bismuth-Containing Quadruple Therapy | Phase 3 | Gastric Ulcer |
| Azilsartan medoxomil and hydrochlorothiazide | Phase 3 | Essential Hypertension |
| Vedolizumab IV | Phase 3 | Ulcerative Colitis |
| Vortioxetine | Phase 3 | Depressive Disorder, Major |
| TAK-438 | Phase 3 | Duodenal Ulcer |
| Lansoprazole | Phase 3 | Gastric Ulcers |
| Alogliptin | Phase 3 | Type 2 Diabetes Mellitus |
| Vedolizumab | Phase 3 | Ulcerative Colitis |
| Brentuximab Vedotin | Phase 2 | Hodgkin Disease |
| Zasocitinib | Phase 3 | Plaque Psoriasis |
Price & technical context
3-month
+14.8%
6-month
+6.5%
12-month
+25.4%
52-wk range
$26.44–$39.20
vs 50-day MA
+3.4%
vs 200-day MA
+9.1%
Realized vol
46.4%
Max drawdown
-24.9%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for TKPHF (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.